Physician profile
Rajeev Gupta
NPI 1659358836
$6,064.17
in general payments reported to CMS, 2019-2025
31 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $483 · 2021: $1,669 · 2022: $998 · 2023: $725 · 2024: $561 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,209.97 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $891.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $565.46 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $559.19 | 2019-2023 | |
| Pfizer INC. | $501.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $302.12 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $259.49 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $250.09 | 2021-2022 | |
| Amgen INC. | $169.73 | 2019-2023 | Otezla, Repatha |
| Mylan Specialty L.P. | $163.00 | 2021-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $157.66 | 2019-2025 | Eliquis |
| Novartis Pharmaceuticals Corporation | $128.24 | 2023 | |
| Abbvie INC. | $100.29 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $92.44 | 2022-2023 | Hetlioz |
| Nestle Healthcare Nutrition INC. | $85.12 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $80.98 | 2020-2022 | |
| Abbott Laboratories | $78.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.23 | 2019-2023 | Glassia |
| Exact Sciences Corporation | $66.16 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $44.85 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $43.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $41.05 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $40.18 | 2021 | |
| Esperion Therapeutics, INC. | $27.52 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.91 | 2021 | |
| Inspire Medical Systems, INC. | $22.33 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $19.79 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.99 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $18.70 | 2024 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $14.31 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.